Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention
Fibrosis, Skin Scarring, Skin Wound
About this trial
This is an interventional treatment trial for Fibrosis focused on measuring Light emitting diode, Light emitting diode-red light, Visible red light, Skin fibrosis, Wound healing, Scarring
Eligibility Criteria
Inclusion Criteria:
- Provision of written informed consent for all study procedures
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Suitable candidate for elective mini-facelift surgery
- Pass a screening photosensitivity test
Exclusion Criteria:
- Current use of any photosensitizing medications
- Light-sensitive conditions
- Diabetes mellitus
- Systemic lupus erythematosus
- Current tobacco use
- History of bleeding or coagulation disorder
- Lax skin associated with genetic disorders
- Open wounds on the face or neck
- Fibrotic skin disease, pre-existing scar(s), or other skin conditions affecting the periauricular skin
- History of surgery or procedure involving or affecting the periauricular skin within the past 6 months (e.g., prior facelift, fillers, laser therapy)
- Tattoos that cover the proposed treatment sites on the periauricular skin
- Any other medical condition(s) that could be compromised by exposure to the proposed treatment
Sites / Locations
- SUNY Downstate Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Sham Comparator
LED-RL phototherapy
Mock irradiation
Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.